Second-generation and newly approved antipsychotics, serum prolactin levels and sexual dysfunctions: a critical literature review

Expert Opinion on Drug Safety
M De HertJoseph Peuskens

Abstract

Using antipsychotic (AP) medication can increase prolactin (PRL) levels and place the patient at risk of sexual dysfunction (SD). The aim of this review is to describe the PRL propensity of the different second-generation and newly approved APs. It then considers the prevalence rates of SDs associated with these compounds in patients with schizophrenia and treatment strategies for the management of SDs and/or hyperprolactinemia (HPRL). Furthermore, we address the lingering question regarding the association between SDs and PRL. SD (particularly long-term) data remain scarce for several APs. A wide variety of assessment techniques used in SD research make reliable comparisons between APs impossible. The majority of these reports do not equally allow us to distinguish between treatment (AP and co-medication)-emergent SDs and illness-related SDs. This makes it difficult to assess the degree to which these side effects are associated with 'PRL-raising' APs, and what part of this fraction is directly reducible to serum PRL levels. Also, few evidence-based treatment strategies for HPRL and associated side effects are available. Therefore, longer-term randomized controlled trials, using reliable and valid structured interviews or ques...Continue Reading

References

May 25, 2016·The Psychiatric Clinics of North America·Donna AmesLynn M Yudofsky
Sep 22, 2015·Frontiers in Neuroscience·Antonio VentriglioAntonello Bellomo
Sep 19, 2015·Current Opinion in Psychiatry·Angel L MontejoFelipe Navarro-Cremades
May 6, 2015·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Isabella PacchiarottiEduard Vieta
Jun 23, 2016·Psychoneuroendocrinology·Itaru MiuraChristoph U Correll
Jul 20, 2016·Journal of Clinical Psychopharmacology·Elena Rubio-AbadalPROLACT Group
Nov 8, 2017·Current Psychiatry Reports·Baptiste PignonAntoine Pelissolo
Jan 21, 2018·World Psychiatry : Official Journal of the World Psychiatric Association (WPA)·Angel L MontejoDavid S Baldwin
Mar 3, 2017·International Clinical Psychopharmacology·Steven G PotkinD Naber
Jun 11, 2018·International Journal of Bipolar Disorders·Joseph R CalabreseHiroaki Kawasaki

Citations

Jan 1, 1991·Experimental and Clinical Endocrinology·P O Lundberg, B Hulter
Feb 6, 1999·Journal of Clinical Psychopharmacology·D L KleinbergM Brecher
Dec 12, 2001·Abdominal Imaging·J-Y ChoiJ-S Choi
May 10, 2002·The Journal of Clinical Psychiatry·Anita H ClaytonAlan Metz
May 22, 2002·The Journal of Clinical Psychiatry·Kwang-Soo KimRuth A Dickson
Jun 27, 2002·Schizophrenia Research·Donna A WirshingWilliam C Wirshing
Sep 25, 2003·Journal of Sex & Marital Therapy·Kenneth Paul RosenbergCharles Gross
Jan 8, 2004·Journal of Clinical Psychopharmacology·Rikus KnegteringRobert J van den Bosch
Mar 9, 2004·The Journal of Clinical Psychiatry·Roberto CavallaroEnrico Smeraldi
Apr 13, 2004·International Clinical Psychopharmacology·Ann MortimerSOLIANOL Sudy Group
Jul 31, 2004·International Journal of Impotence Research·M AtmacaE Tezcan
Aug 3, 2004·The American Journal of Psychiatry·Stephen R MarderSteven Shon
Dec 2, 2004·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Pierre ChueAnthony S David
Mar 16, 2005·The Journal of Clinical Psychiatry·Mark OlfsonEskinder Tafesse
Aug 12, 2005·Mayo Clinic Proceedings·Mark E Molitch
Sep 21, 2005·The New England Journal of Medicine·Jeffrey A LiebermanClinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators
Nov 12, 2005·Journal of Clinical Psychopharmacology·Angel Luis Montejo GonzálezSpanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction
May 20, 2006·Journal of Sex & Marital Therapy·Henderikus KnegteringDurk Wiersma
Jul 20, 2006·The Journal of Clinical Psychiatry·Anita H Clayton
Oct 7, 2006·Nature Clinical Practice. Endocrinology & Metabolism·Vincent GoffinPaul A Kelly
Jan 31, 2007·São Paulo Medical Journal = Revista Paulista De Medicina·Anna Maria Niccolai CostaJair de Jesus Mari
Mar 16, 2007·Acta Psychiatrica Scandinavica·J EberhardS Levander
Mar 1, 2008·Journal of Psychopharmacology·Amna MirKatherine J Aitchison
Mar 15, 2008·Human Psychopharmacology·Martin Baggaley
May 24, 2008·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Angel L Montejo
Apr 9, 2008·Advances in Psychosomatic Medicine·Zvi Zemishlany, Abraham Weizman
Apr 9, 2008·Psychoneuroendocrinology·Henderikus KnegteringJim van Os
Apr 15, 2008·International Clinical Psychopharmacology·Victor PerezTESIS Study Group

Related Concepts

PBX1 wt Allele
Antipsychotic Effect
Schizophrenia
Hyperprolactinemia
Antipsychotic Agents
PRL gene
Prolactin Measurement
Prolactin Binding
PRL wt Allele
Organic Sexual Dysfunction

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here